Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NextCure Inc (NXTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: NXTC (1-star) is a SELL. SELL since 1 days. Profits (-16.36%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $3
1 Year Target Price $3
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -58.88% | Avg. Invested days 21 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.62M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 2 | Beta 1.08 | 52 Weeks Range 0.22 - 1.82 | Updated Date 06/30/2025 |
52 Weeks Range 0.22 - 1.82 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.77 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.39% | Return on Equity (TTM) -63.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -38122453 | Price to Sales(TTM) 9.52 |
Enterprise Value -38122453 | Price to Sales(TTM) 9.52 | ||
Enterprise Value to Revenue 1.62 | Enterprise Value to EBITDA 0.51 | Shares Outstanding 28050200 | Shares Floating 20654758 |
Shares Outstanding 28050200 | Shares Floating 20654758 | ||
Percent Insiders 8.91 | Percent Institutions 48.29 |
Analyst Ratings
Rating 2 | Target Price 3 | Buy 2 | Strong Buy - |
Buy 2 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
NextCure Inc
Company Overview
History and Background
NextCure, Inc. was founded in 2015 and is a biopharmaceutical company focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company is based on the work of Dr. Lieping Chen, a pioneer in immuno-oncology.
Core Business Areas
- Research and Development: Focused on discovering and developing novel immunomedicines.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates.
- Drug Discovery Platform: Utilizing its proprietary FIND-IO platform to identify and validate novel immuno-oncology targets.
Leadership and Structure
Michael Richman is the President and Chief Executive Officer. The company has a board of directors overseeing strategy. The organizational structure includes departments for research, development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- NC410: A LAIR-1 antagonist antibody being developed for solid tumors. Currently in clinical trials. Competitors include companies developing similar immuno-oncology therapies, such as Merck (Keytruda), Bristol-Myers Squibb (Opdivo), and Roche (Tecentriq).
- NC762: An anti-B7-H4 antibody being developed for solid tumors. Currently in preclinical stage. Competitors include companies developing anti-B7-H4 therapies.
Market Dynamics
Industry Overview
The immuno-oncology market is a rapidly growing segment of the pharmaceutical industry, with significant potential for new therapies targeting cancer and other immune-related diseases. Competition is fierce.
Positioning
NextCure is positioned as an innovative biopharmaceutical company with a unique drug discovery platform targeting novel immuno-oncology pathways. Its competitive advantage lies in its focus on previously unexplored immune mechanisms.
Total Addressable Market (TAM)
The TAM for immuno-oncology is projected to be substantial, potentially exceeding $100 billion annually. NextCure aims to capture a portion of this market by developing novel therapies for cancer.
Upturn SWOT Analysis
Strengths
- Novel Drug Discovery Platform (FIND-IO)
- Experienced Leadership Team
- Focus on Innovative Immuno-Oncology Targets
- Strong Patent Portfolio
Weaknesses
- Limited Financial Resources
- Early-Stage Clinical Pipeline
- Reliance on Collaboration and Funding
- High Attrition Rate in Drug Development
Opportunities
- Strategic Partnerships and Licensing Agreements
- Expansion of Clinical Pipeline
- Positive Clinical Trial Results
- Increased Adoption of Immuno-Oncology Therapies
Threats
- Competition from Larger Pharmaceutical Companies
- Clinical Trial Failures
- Regulatory Hurdles
- Market Access and Reimbursement Challenges
Competitors and Market Share
Key Competitors
- Merck (MRK)
- Bristol-Myers Squibb (BMY)
- Roche (RHHBY)
- AstraZeneca (AZN)
Competitive Landscape
NextCure faces intense competition from larger pharmaceutical companies with established immuno-oncology franchises. Its advantages lie in its novel drug discovery platform and focus on previously unexplored immune mechanisms. Disadvantages stem from limited resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by the progress of its clinical pipeline and the expansion of its drug discovery platform. Recent growth rates are tied to funding rounds and collaborations.
Future Projections: Future growth is dependent on the success of its clinical trials and the ability to secure partnerships and funding. Analyst projections would vary based on clinical data and market trends.
Recent Initiatives: Recent initiatives include advancing NC410 and NC762 through clinical development, expanding collaborations, and securing additional funding.
Summary
NextCure is a promising, yet high-risk, clinical-stage biopharmaceutical company with an innovative drug discovery platform. Its success hinges on positive clinical trial results and securing strategic partnerships. The company needs to carefully manage its cash burn and navigate the competitive landscape of the immuno-oncology market. Clinical trial failures pose a significant threat to the companyu2019s viability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NextCure Inc
Exchange NASDAQ | Headquaters Beltsville, MD, United States | ||
IPO Launch date 2019-05-09 | Co-Founder, CEO, President & Director Mr. Michael S. Richman MSBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 43 | Website https://www.nextcure.com |
Full time employees 43 | Website https://www.nextcure.com | ||
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.